[서울=뉴스핌] Reporter Yang-seop Kim = Research results of ‘BTN1A1’, a new immune checkpoint protein discovered by STCube, a biotechnology company that develops immunotherapy, is scheduled to enter global clinical trials at ‘2021 AACR-NCI-EORTC’, which will be held online from the 7th to the 10th of next month. announced on the 15th that it will be announced.
‘AACR-NCI-EORTC’, which STCube attends this time, is a regular event co-hosted by the world’s most prestigious cancer research institutes, including the American Cancer Society (AACR), the National Cancer Institute (NCI), and the European Cancer Society (EORTC). As an academic event, it is considered one of the most influential conferences in the field of cancer treatment. In April, ST Cube attended ‘AACR 2021’ and announced the research results of ‘BTN1A1’, a new immune checkpoint protein, and received great attention from global pharmaceutical companies.
‘BTN1A1’, an immune checkpoint inhibitor target discovered by ST Cube for the first time in the world, is an immune checkpoint protein that inhibits the proliferation of T cells, which are immune cells, and inhibits the apoptosis effect of T cells. It is a novel immune checkpoint inhibitor that is completely different from the existing immune checkpoint inhibitor targets, ‘PD-1’ and ‘PD-L1’, and it has been found that expression is limited in normal tissue cells, but it is expressed up to 80% in various cancer cells.
At this conference, ST Cube plans to present the results of additional unknown studies on the protein that binds to ‘BTN1A1’. ST Cube discovered that ‘BTN1A1’ binds to Gal-9 for the first time in the world, and it was confirmed that when ‘BTN1A1’ binds to Gal-9, it inhibits T cell activity.
In addition, it was confirmed that a conjugate to which BTN1A1-Gal-9-PD-1 binds via Gal-9 was formed. There is a report that the prognosis of cancer worsens when Gal-9 is expressed in cancer patients.
In July, STCube obtained positive results in the primate toxicity test, which is the last and most important preclinical test, for the ‘hSTC810’ antibody targeting ‘BTN1A1’, and obtained the final result that no abnormal symptoms were found in all safety tests.
A company official said, “I participated in the AACR in April and the BIO USA conference in June and received a lot of interest and response to the hSTC810 antibody targeting ‘BTN1A1’. We plan to create a good opportunity with global pharmaceutical companies along with the start of clinical trials through the publication of papers, etc.”, he said. “The global clinical preparation process is proceeding smoothly,” he added.